Frontline MM State of the Art: Can We Prolong PFS With D-VTd in ASCT-Eligible Disease? Does D-RVd Improve sCR Rates & MRD Negativity? Is D-VMP the Best Choice for Transplant-Ineligible Pts?

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Playback speed

10 seconds

Frontline MM State of the Art: Can We Prolong PFS With D-VTd in ASCT-Eligible Disease? Does D-RVd Improve sCR Rates & MRD Negativity? Is D-VMP the Best Choice for Transplant-Ineligible Pts?

By Claudio Cerchione 34 Videos

85 views

February 3, 2021

0 Comments

ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…

Feat. D. Tremblay

Treatment-Related Quality of Life in MF

Feat. A. Hunter

Shingles (Herpes Zoster) Vaccination in Adults: What is the Importan…

21:05

Louisville Hematology Highlights

Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Feat. R. Gale

17:46

Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Highlights in 1L MM - Quadruplet Therapies …

Feat. A. Jakubowiak

16:42

Insights from 2023 ASH Annual Meeting

ASH 2023 Summary: "The Best of Myeloma - Highlights & Key T…

Feat. H. Hashmi

19:24

Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Updates on Managing Newly Diagnosed MM - In…

Feat. P. Richardson

20:19

Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Highlights of Hematologic Malignancies - …

Feat. A. Paulus

06:19

Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Dara-KRd in NDMM Without ASCT - Final Analy…

Feat. B. Derman

49:01

Scripps MD Anderson Cancer Center

Current Summary of the Multiple Myeloma Treatment Landscape

Feat. R. Lu

12:35

Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Treatment Options for Patients With Myelo…

Feat. C. Cerchione

16:28

Total Health

Multiple Myeloma: A New Risk-Adapted Approach

Feat. J. Chandler

09:51

i3 Health

MRD Testing in Leukemias: When Negativity Is a Positive Thing

Feat. N. S. Raje

08:36

Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Standard- and High-Risk ND Transplant-Eligi…

Feat. N. Joseph

31:51

Indy Hematology Review

Treating Multiple Myeloma: The Cure Is Within Reach - Goals of Curre…

Feat. K. Anderson

11:38

Heinz Ludwig

Maintenance Therapy in Myeloma: Which Agent and for How Long?

03:17

Insights from 2023 IMS Annual Meeting

IMS 2023 Insights: "Highlights From the International Myeloma S…

Feat. J. Richter

06:23

Integrity Continuing Education

ASH 2023 Insights: "PERSEUS Study - Daratumumab With VRd vs. VR…

Feat. O. Landgren

13:18

Insights from 2023 IMS Annual Meeting

Highlights and Key Takeaways From the 2023 International Myeloma Soc…

Feat. A. Jakubowiak

04:15

Indy Hematology Review

Indy Hematology Review 2023: Plasma Cell Neoplasms and Amyloidosis U…

Feat. M. Gertz

21:51

Moffitt Cancer Center

State-of-the-Art: Bispecific Antibodies in Myeloma - Which? How? Whe…

Feat. A. Grajales-Cruz

05:47

Meletios Dimopoulos

Login

Login

Join VuMedi

Frontline MM State of the Art: Can We Prolong PFS With D-VTd in ASCT-Eligible Disease? Does D-RVd Improve sCR Rates & MRD Negativity? Is D-VMP the Best Choice for Transplant-Ineligible Pts?

Related Content